Optimizing screening and management of cardiovascular health in prostate cancer: A review

Authors

  • Miran Kenk Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON
  • Jean C. Grégoire Montreal Heart Institute, Montreal, QC
  • Marc-Andre Coté Centre hospitalier universitaire de Quebec 1050 ch Sainte-Foy Québec QC G1S 4L8
  • Kim A. Connelly St. Michael's Hospital Li Ka Shing Knowledge Institute 30 Bond St. Toronto, ON M5B 1W8
  • Margot K. Davis The University of British Columbia Diamond Health Care Center 2775 Laurel St 10th Floor Vancouver, BC V5Z 1M9
  • George Dresser Division of Clinical Pharmacology Department of Medicine Western University London, Ontario, Canada
  • Nina Ghosh Queensway Carleton Hospital University of Ottawa Heart Institute, Ottawa, ON
  • Shaun Goodman Division of Cardiology, St. Michael's Hospital, Toronto, ON
  • Christopher Johnson Christopher Johnson, MD, FRCPC Division of Cardiology University of Ottawa Ottawa, ON
  • Neil Fleshner Princess Margaret Hospital, Toronto, ON

DOI:

https://doi.org/10.5489/cuaj.6685

Keywords:

androgen deprivation therapy, cardiovascular risk, prostate cancer

Abstract

In clinical practice, cancer management does not consistently encompass screening and identification of cardiovascular (CV) risk. The use of androgen deprivation therapy (ADT) in prostate cancer has been associated with increased CV risk and development of metabolic syndrome, necessitating identification of patients at risk in this population (e.g., those with pre-existing CV disease). A multidisciplinary team of Canadian physicians was assembled to develop a series of recommendations intended to identify patients who may benefit from optimal management of their CV disease and/or modification of cardiac risk factors. A key goal was the development of a simple screening tool for identification of patients with pre-existing CV disease. This simple and inclusive set of recommendations are intended for use within urology clinics to facilitate holistic approaches and simplify the management of patients.

Downloads

Download data is not yet available.

Downloads

Published

2020-06-01

How to Cite

Kenk, M., Grégoire , J., Coté, M.-A. ., Connelly, K. A., Davis, M. K. ., Dresser, G. ., Ghosh, N. ., Goodman, S., Johnson, C. ., & Fleshner, N. (2020). Optimizing screening and management of cardiovascular health in prostate cancer: A review. Canadian Urological Association Journal, 14(9), E458–64. https://doi.org/10.5489/cuaj.6685

Issue

Vol. 14 No. 9 (2020): CUAJ September

Section

Review

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.